Telik, Inc.  

(Public, NASDAQ:TELK)   Watch this stock  
Find more results for TELK
-0.01 (-0.74%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.34 - 1.35
52 week 1.05 - 2.15
Open 1.34
Vol / Avg. 0.00/85,389.00
Mkt cap 6.14M
P/E     -
Div/yield     -
EPS -1.18
Shares 4.58M
Beta 0.49
Inst. own 5%

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -99.99% -126.97%
Return on average equity -153.94% -221.75%
Employees 22 -
CDP Score - -


United States - Map
+1-650-8457700 (Phone)
+1-650-8457800 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company´┐Żs drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In June 2011, the Company initiated a Phase II clinical trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. As of December 31, 2011, Telik had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphom and multiple myeloma.

Officers and directors

Michael M. Wick M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Wendy K. Wee Principal Financial and Accounting Officer, Vice President - Finance, Controller
Age: 60
Bio & Compensation  - Reuters
William P. Kaplan Esq. Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Age: 59
Bio & Compensation  - Reuters
Steven R. Schow Ph.D. Vice President - Research
Age: 63
Bio & Compensation  - Reuters
Edward W. Cantrall Ph.D. Independent Director
Age: 81
Bio & Compensation  - Reuters
Steven R. Goldring M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Richard B. Newman Esq. Independent Director
Age: 74
Bio & Compensation  - Reuters